dacarbazine has been researched along with thymosin in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ameglio, F; Carpano, S; Cavaliere, R; Di Lauro, L; Frasca, AM; Lopez, M; Pignatti, F; Rosselli, M; Vici, P; Vitelli, G | 1 |
| Garaci, E; Izzo, F; Pierimarchi, P; Ranuzzi, M; Rasi, G; Sinibaldi-Vallebona, P; Terzoli, E; Tuthill, C | 1 |
| Camerini, R; Cognetti, F; Ferraresi, V; Garbe, C; Gascon, P; Gilde, K; Guillot, B; Jassem, J; Lesimple, T; Mackiewicz, A; Maio, M; Testori, A; Trefzer, U | 1 |
| Calabrò, L; Danielli, R; Di Giacomo, AM; Fonsatti, E; Maio, M | 1 |
1 review(s) available for dacarbazine and thymosin
| Article | Year |
|---|---|
Thymosin α1 in melanoma: from the clinical trial setting to the daily practice and beyond.
Topics: Antineoplastic Agents, Alkylating; Clinical Trials, Phase II as Topic; Dacarbazine; Humans; Immunologic Factors; Immunotherapy; Melanoma; Randomized Controlled Trials as Topic; Thymosin | 2012 |
3 trial(s) available for dacarbazine and thymosin
| Article | Year |
|---|---|
Biochemotherapy with thymosin alpha 1, interleukin-2 and dacarbazine in patients with metastatic melanoma: clinical and immunological effects.
Topics: Adult; Aged; CD4 Antigens; CD8 Antigens; Combined Modality Therapy; Dacarbazine; Female; Humans; Interleukin-2; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Remission Induction; Skin Neoplasms; Thymalfasin; Thymosin | 1994 |
Combined treatment with thymosin-alpha1 and low dose interferon-alpha after dacarbazine in advanced melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Combined Modality Therapy; Dacarbazine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Feasibility Studies; Female; Humans; Immunologic Factors; Interferon alpha-2; Interferon-alpha; Killer Cells, Natural; Lymphopenia; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Recombinant Proteins; Safety; Survival Analysis; Thymalfasin; Thymosin; Treatment Outcome | 2000 |
Large randomized study of thymosin alpha 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Interferon-alpha; Male; Melanoma; Middle Aged; Thymalfasin; Thymosin | 2010 |